255 related articles for article (PubMed ID: 17118172)
1. Role of nonhuman primate models in the discovery and clinical development of selective progesterone receptor modulators (SPRMs).
Chwalisz K; Garg R; Brenner R; Slayden O; Winkel C; Elger W
Reprod Biol Endocrinol; 2006; 4 Suppl 1(Suppl 1):S8. PubMed ID: 17118172
[TBL] [Abstract][Full Text] [Related]
2. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis.
Chwalisz K; Perez MC; Demanno D; Winkel C; Schubert G; Elger W
Endocr Rev; 2005 May; 26(3):423-38. PubMed ID: 15857972
[TBL] [Abstract][Full Text] [Related]
3. Discovery, chemistry, and reproductive pharmacology of asoprisnil and related 11beta-benzaldoxime substituted selective progesterone receptor modulators (SPRMs).
Schubert G; Elger W; Kaufmann G; Schneider B; Reddersen G; Chwalisz K
Semin Reprod Med; 2005 Feb; 23(1):58-73. PubMed ID: 15714390
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential for the selective progesterone receptor modulator asoprisnil in the treatment of leiomyomata.
Chwalisz K; DeManno D; Garg R; Larsen L; Mattia-Goldberg C; Stickler T
Semin Reprod Med; 2004 May; 22(2):113-9. PubMed ID: 15164306
[TBL] [Abstract][Full Text] [Related]
5. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Murji A; Whitaker L; Chow TL; Sobel ML
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
[TBL] [Abstract][Full Text] [Related]
6. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata.
Williams AR; Critchley HO; Osei J; Ingamells S; Cameron IT; Han C; Chwalisz K
Hum Reprod; 2007 Jun; 22(6):1696-704. PubMed ID: 17339234
[TBL] [Abstract][Full Text] [Related]
7. Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy.
DeManno D; Elger W; Garg R; Lee R; Schneider B; Hess-Stumpp H; Schubert G; Chwalisz K
Steroids; 2003 Nov; 68(10-13):1019-32. PubMed ID: 14667995
[TBL] [Abstract][Full Text] [Related]
8. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy.
Wilkens J; Chwalisz K; Han C; Walker J; Cameron IT; Ingamells S; Lawrence AC; Lumsden MA; Hapangama D; Williams AR; Critchley HO
J Clin Endocrinol Metab; 2008 Dec; 93(12):4664-71. PubMed ID: 18765509
[TBL] [Abstract][Full Text] [Related]
9. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications.
Chabbert-Buffet N; Meduri G; Bouchard P; Spitz IM
Hum Reprod Update; 2005; 11(3):293-307. PubMed ID: 15790602
[TBL] [Abstract][Full Text] [Related]
10. A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells.
Chen W; Ohara N; Wang J; Xu Q; Liu J; Morikawa A; Sasaki H; Yoshida S; Demanno DA; Chwalisz K; Maruo T
J Clin Endocrinol Metab; 2006 Apr; 91(4):1296-304. PubMed ID: 16464945
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials.
Stewart EA; Diamond MP; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
Hum Reprod; 2019 Apr; 34(4):623-634. PubMed ID: 30865281
[TBL] [Abstract][Full Text] [Related]
12. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth.
Yoshida S; Ohara N; Xu Q; Chen W; Wang J; Nakabayashi K; Sasaki H; Morikawa A; Maruo T
Semin Reprod Med; 2010 May; 28(3):260-73. PubMed ID: 20414849
[TBL] [Abstract][Full Text] [Related]
13. A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator.
Madauss KP; Grygielko ET; Deng SJ; Sulpizio AC; Stanley TB; Wu C; Short SA; Thompson SK; Stewart EL; Laping NJ; Williams SP; Bray JD
Mol Endocrinol; 2007 May; 21(5):1066-81. PubMed ID: 17356170
[TBL] [Abstract][Full Text] [Related]
14. Estrogen-induced stromal cell-derived factor-1 (SDF-1/Cxcl12) expression is repressed by progesterone and by Selective Estrogen Receptor Modulators via estrogen receptor alpha in rat uterine cells and tissues.
Glace L; Grygielko ET; Boyle R; Wang Q; Laping NJ; Sulpizio AC; Bray JD
Steroids; 2009; 74(13-14):1015-24. PubMed ID: 19665469
[TBL] [Abstract][Full Text] [Related]
15. Selective progesterone receptor modulator asoprisnil induces endoplasmic reticulum stress in cultured human uterine leiomyoma cells.
Xu Q; Ohara N; Liu J; Nakabayashi K; DeManno D; Chwalisz K; Yoshida S; Maruo T
Am J Physiol Endocrinol Metab; 2007 Oct; 293(4):E1002-11. PubMed ID: 17652152
[TBL] [Abstract][Full Text] [Related]
16. Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN.
Wilkens J; Williams AR; Chwalisz K; Han C; Cameron IT; Critchley HO
Hum Reprod; 2009 May; 24(5):1036-44. PubMed ID: 19176543
[TBL] [Abstract][Full Text] [Related]
17. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata.
Chwalisz K; Larsen L; Mattia-Goldberg C; Edmonds A; Elger W; Winkel CA
Fertil Steril; 2007 Jun; 87(6):1399-412. PubMed ID: 17307170
[TBL] [Abstract][Full Text] [Related]
18. A novel selective progesterone receptor modulator asoprisnil activates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated signaling pathway in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells.
Sasaki H; Ohara N; Xu Q; Wang J; DeManno DA; Chwalisz K; Yoshida S; Maruo T
J Clin Endocrinol Metab; 2007 Feb; 92(2):616-23. PubMed ID: 17105846
[TBL] [Abstract][Full Text] [Related]
19. Selective Progesterone Receptor Modulators-Mechanisms and Therapeutic Utility.
Islam MS; Afrin S; Jones SI; Segars J
Endocr Rev; 2020 Oct; 41(5):. PubMed ID: 32365199
[TBL] [Abstract][Full Text] [Related]
20. Selective progesterone receptor modulators: current applications and perspectives.
Chabbert-Buffet N; Kolanska K; Daraï E; Bouchard P
Climacteric; 2018 Aug; 21(4):375-379. PubMed ID: 29338440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
